Intravenous Nimodipine West European Stroke Trial "INWEST"

Terminated

Phase N/A Results

Results

Patients in the 2 mg/h intravenous nimodipine group showed a significantly worse outcome at 21 days compared to the placebo group (p = 0.0005 for the Orgogozo scale and p = 0.0033 for the Barthel Index). Patients in the 1 mg/h intravenous nimodipine group also showed worse outcome at 21 days but the difference was not statistically significant (p >= 0.02 for the Orgogozo scale and p >= 0.005 for the Barthel Index). After 24 weeks, the differences became more pronounced.